XERS | tickerfilter.com

Fundamental analysis

30%

Profitability 15%

Dept financing 25%

Liquidity 75%

Performance 35%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.35%

1 Month

12.94%

3 Months

26.45%

6 Months

65.40%

1 Year

66.99%

2 Year

176.98%

Key data

Stock price

$2.90

P/E Ratio

-7.03

DAY RANGE

$2.90 - $3.40

EPS

-$0.42

52 WEEK RANGE

$1.75 - $3.87

52 WEEK CHANGE

$66.99

MARKET CAP

418.687 M

YIELD

N/A

SHARES OUTSTANDING

148.999 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

1.76

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,666,031

AVERAGE 30 VOLUME

$1,735,123

Company detail

CEO: Paul R. Edick
Region: US
Website: xerispharma.com
Employees: 290
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Xeris Biopharma Holdings, Inc. engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis, a therapy for the. treatment of hyperkalemic, hypokalemic. and related variants of primary periodic paralysis.

XERS - Xeris Biopharma Holdings, Inc.